tbuckley/cabot-search huggingface dataset:
Rare Intraosseous Cavernous Hemangioma of the Orbit
Authors: Brian T. Soetikno, Chaow Charoenkijkajorn, Natalie A. Homer
Journal: Ophthalmology (2023)

A healthy 52-year-old man presented with a painless, enlarging, right lateral orbital nodule of 1-year duration (A, arrow). Clinical examination revealed a 2.3-cm firm immobile lateral orbital rim mass. Computed tomography displayed an expansile and osteolytic neoplasm of the zygoma with orbital and extraorbital extension (B). Lateral orbitotomy exposed a porous neoplasm of the anterior zygomatic face (C). The exophytic component was resected, and histopathological examination demonstrated multiple, dilated, blood-filled cavities between bony trabeculae, consistent with a benign intraosseous cavernous hemangioma (D).
Microbial genes outperform species and SNVs as diagnostic markers for Crohn’s disease on multicohort fecal metagenomes empowered by artificial intelligence
Authors: Sheng Gao, Xiang Gao, Ruixin Zhu, Dingfeng Wu, Zhongsheng Feng, Na Jiao, Ruicong Sun, Wenxing Gao, Qing He, Zhanju Liu, Lixin Zhu
Journal: Gut Microbes (2023)

Dysbiosis of gut microbial community is associated with the pathogenesis of CD and may serve as a promising noninvasive diagnostic tool. We aimed to compare the performances of the microbial markers of different biological levels by conducting a multidimensional analysis on the microbial metagenomes of CD. We collected fecal metagenomic datasets generated from eight cohorts that altogether include 870 CD patients and 548 healthy controls. Microbial alterations in CD patients were assessed at multidimensional levels including species, gene, and SNV level, and then diagnostic models were constructed using artificial intelligence algorithm. A total of 227 species, 1047 microbial genes, and 21,877 microbial SNVs were identified that differed between CD and controls. The species, gene, and SNV models achieved an average AUC of 0.97, 0.95, and 0.77, respectively. Notably, the gene model exhibited superior diagnostic capability, achieving an average AUC of 0.89 and 0.91 for internal and external validations, respectively. Moreover, the gene model was specific for CD against other microbiome-related diseases. Furthermore, we found that phosphotransferase system (PTS) contributed substantially to the diagnostic capability of the gene model. The outstanding performance of PTS was mainly explained by genes celB and manY, which demonstrated high predictabilities for CD with metagenomic datasets and was validated in an independent cohort by qRT-PCR analysis. Our global metagenomic analysis unravels the multidimensional alterations of the microbial communities in CD and identifies microbial genes as robust diagnostic biomarkers across geographically and culturally distinct cohorts.
The Routine Treatment of Diabetes With Insulin
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor
Authors: Ronald J. Sokol, Emmanuel M. Gonzales, Binita M. Kamath, Alastair Baker, Pamela Vig, Douglas B. Mogul, Will Garner, Bettina E. Hansen, Emmanuel Jacquemin, Richard J. Thompson
Journal: Hepatology (2023)

Background and Aims: Refractory pruritus and other complications of cholestasis are indications for liver transplantation (LT) in patients with Alagille syndrome (ALGS). We evaluated predictors of event-free survival and transplant-free survival in patients with ALGS treated with maralixibat (MRX), an ileal bile acid transporter inhibitor. Approach and Results: We assessed patients with ALGS from 3 clinical trials of MRX with up to 6 years of follow-up. Event-free survival was defined as the absence of LT, surgical biliary diversion, hepatic decompensation, or death; transplant-free survival was the absence of LT or death. Forty-three potential predictors were evaluated, including age, pruritus (ItchRO[Obs] 0–4 scale), biochemistries, platelets, and serum bile acids. Harrell’s concordance statistic assessed goodness-of-fit, and then, Cox proportional hazard models confirmed the statistical significance of the predictors identified. A further analysis was performed to identify cutoffs using a grid search. Seventy-six individuals met the criteria of receiving MRX for ≥48 weeks with laboratory values available at week 48 (W48). The median duration of MRX was 4.7 years (IQR: 1.6–5.8); 16 had events (10 LT, 3 decompensation, 2 death, and 1 surgical biliary diversion). The 6-year event-free survival improved with a clinically meaningful &gt;1-point ItchRO(Obs) reduction from baseline to W48 (88% vs. 57%; p = 0.005), W48 bilirubin &lt; 6.5 mg/dL (90% vs. 43%; p &lt; 0.0001), and W48 serum bile acid &lt; 200 µmol/L (85% vs. 49%; p = 0.001). These parameters were also predictive of 6-year transplant-free survival. Conclusions: Improvement in pruritus by 48 weeks, and lower W48 bilirubin and serum bile acid levels were associated with fewer events. These data may help identify potential markers of disease progression for ALGS patients treated with MRX.
Disrespectful Conduct in the Medical Profession
Authors: Pamela S. Douglas
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The importance of soft tissue condition in bone regenerative procedures to ensure long‐term peri‐implant health
Authors: Mario Roccuzzo, Andrea Roccuzzo, Crystal Marruganti, Stefan Fickl
Journal: Periodontology 2000 (2023)

Abstract Bone regenerative procedures have been widely proved to be a reliable treatment option to re‐create the ideal pre‐implant clinical conditions. Nevertheless, these techniques are not free from post‐operative complications which might result in implant failure. Consequently, as demonstrated by the increasing recently published evidence, a careful pre‐ and intra‐operative flap evaluation to ensure an ideal and hermetic tension‐free wound closure is of paramount importance to successfully treat bony defects. In this respect, several surgical interventions mainly aimed to increase the amount of keratinized mucosa either to allow an optimal healing after a reconstructive procedure or to establish an optimal peri‐implant soft tissue seal have been proposed. The present review summarizes the level of evidence on the surgical clinical aspects which have an impact on the soft tissue handling associated with bone reconstructive procedures and on the importance of soft tissue conditions to enhance and maintain peri‐implant health in the long‐term.
Intramedullary Nailing vs Sliding Hip Screw in Trochanteric Fracture Management
Authors: Emil H. Schemitsch, Lauren L. Nowak, Arndt P. Schulz, Ole Brink, Rudolf W. Poolman, Samir Mehta, Dirk Stengel, Chang Qing Zhang, Saul Martinez, Bernd Kinner, Timothy J.S. Chesser, Mohit Bhandari, Julio C. Garcia, Mmampapatla Ramokgopa, Robert Probe, Robert Hymes, Andrew Marcantonio, Saqib Rehman, Edward Rodriguez, Saam Morshed, Deniz Baysal, Jeremy Hall, Ted Tufescu, Andrew Bucknill, Hrumitsu Ichimura, Vidar Punsvik, Andrew McAndrew, Goray Datta, Gunasekaran Kumar, Junlin Zhou, Gang Feng
Journal: JAMA Network Open (2023)

Fractures of the hip have devastating effects on function and quality of life. Intramedullary nails (IMN) are the dominant implant choice for the treatment of trochanteric fractures of the hip. Higher costs of IMNs and inconclusive benefit in comparison with sliding hip screws (SHSs) convey the need for definitive evidence.To compare 1-year outcomes of patients with trochanteric fractures treated with the IMN vs an SHS.This randomized clinical trial was conducted at 25 international sites across 12 countries. Participants included ambulatory patients aged 18 years and older with low-energy trochanteric (AO Foundation and Orthopaedic Trauma Association [AO/OTA] type 31-A1 or 31-A2) fractures. Patient recruitment occurred between January 2012 and January 2016, and patients were followed up for 52 weeks (primary end point). Follow-up was completed in January 2017. The analysis was performed in July 2018 and confirmed in January 2022.Surgical fixation with a Gamma3 IMN or an SHS.The primary outcome was health-related quality of life (HRQOL), measured by the EuroQol-5 Dimension (EQ5D) at 1-year postsurgery. Secondary outcomes included revision surgical procedure, fracture healing, adverse events, patient mobility (measured by the Parker mobility score), and hip function (measured by the Harris hip score).In this randomized clinical trial, 850 patients were randomized (mean [range] age, 78.5 [18-102] years; 549 [64.6% female) with trochanteric fractures to undergo fixation with either the IMN (n = 423) or an SHS (n = 427). A total of 621 patients completed follow-up at 1 year postsurgery (304 treated with the IMN [71.9%], 317 treated with an SHS [74.2%]). There were no significant differences between groups in EQ5D scores (mean difference, 0.02 points; 95% CI, -0.03 to 0.07 points; P = .42). Furthermore, after adjusting for relevant covariables, there were no between-group differences in EQ5D scores (regression coefficient, 0.00; 95% CI, -0.04 to 0.05; P = .81). There were no between-group differences for any secondary outcomes. There were also no significant interactions for fracture stability (β [SE] , 0.01 [0.05]; P = .82) or previous fracture (β [SE], 0.01 [0.10]; P = .88) and treatment group.This randomized clinical trial found that IMNs for the treatment of trochanteric fractures had similar 1-year outcomes compared with SHSs. These results suggest that the SHS is an acceptable lower-cost alternative for trochanteric fractures of the hip.ClinicalTrials.gov Identifier: NCT01380444.
Direct assessment of microcirculation in shock: a randomized-controlled multicenter study
Authors: Raphael Romano Bruno, Jakob Wollborn, Karl Fengler, Moritz Flick, Christian Wunder, Sebastian Allgäuer, Holger Thiele, Mara Schemmelmann, Johanna Hornemann, Helene Mathilde Emilie Moecke, Filiz Demirtas, Lina Palici, Marcus Franz, Bernd Saugel, Eduardo Kattan, Daniel De Backer, Jan Bakker, Glenn Hernandez, Malte Kelm, Christian Jung
Journal: Intensive Care Medicine (2023)

Shock is a life-threatening condition characterized by substantial alterations in the microcirculation. This study tests the hypothesis that considering sublingual microcirculatory perfusion variables in the therapeutic management reduces 30-day mortality in patients admitted to the intensive care unit (ICU) with shock. This randomized, prospective clinical multicenter trial-recruited patients with an arterial lactate value above two mmol/L, requiring vasopressors despite adequate fluid resuscitation, regardless of the cause of shock. All patients received sequential sublingual measurements using a sidestream-dark field (SDF) video microscope at admission to the intensive care unit (± 4 h) and 24 (± 4) hours later that was performed blindly to the treatment team. Patients were randomized to usual routine or to integrating sublingual microcirculatory perfusion variables in the therapy plan. The primary endpoint was 30-day mortality, secondary endpoints were length of stay on the ICU and the hospital, and 6-months mortality. Overall, we included 141 patients with cardiogenic (n = 77), post cardiac surgery (n = 27), or septic shock (n = 22). 69 patients were randomized to the intervention and 72 to routine care. No serious adverse events (SAEs) occurred. In the interventional group, significantly more patients received an adjustment (increase or decrease) in vasoactive drugs or fluids (66.7% vs. 41.8%, p = 0.009) within the next hour. Microcirculatory values 24 h after admission and 30-day mortality did not differ [crude: 32 (47.1%) patients versus 25 (34.7%), relative risk (RR) 1.39 (0.91–1.97); Cox-regression: hazard ratio (HR) 1.54 (95% confidence interval (CI) 0.90–2.66, p = 0.118)]. Integrating sublingual microcirculatory perfusion variables in the therapy plan resulted in treatment changes that do not improve survival at all.
A Gap Between Evidence-Based Research and Clinical Practice in Management of Hip Fractures
Authors: Mai P. Nguyen, Marc F. Swiontkowski
Journal: JAMA Network Open (2023)

Emil H. Schemitsch, MD; Lauren L. Nowak, PhD; Arndt P. Schulz, MD, PhD; Ole Brink, MD; Rudolf W. Poolman, MD, PhD; Samir Mehta, MD; Dirk Stengel, MD, PhD, MSc; Chang Qing Zhang, MD, PhD; Saul Martinez, MD; Bernd Kinner, MD, PhD; Timothy J.S. Chesser, FRCS; Mohit Bhandari, MD, PhD, FRCSC; INSITE Investigators; Julio C. Garcia; Mmampapatla Ramokgopa; Robert Probe; Robert Hymes; Andrew Marcantonio; Saqib Rehman; Edward Rodriguez; Saam Morshed; Deniz Baysal; Jeremy Hall; Ted Tufescu; Andrew Bucknill; Hrumitsu Ichimura; Vidar Punsvik; Andrew McAndrew; Goray Datta; Gunasekaran Kumar; Junlin Zhou; Gang Feng
Yeast cell membrane-camouflaged PLGA nanoparticle platform for enhanced cancer therapy
Authors: Yu He, Qi-Wen Chen, Jin-Xin Yu, Si-Yong Qin, Wen-Long Liu, Yi-Han Ma, Xiao-Sui Chen, Ai-Qing Zhang, Xian-Zheng Zhang, Yin-Jia Cheng
Journal: Journal of Controlled Release (2023)
Broad and Durable Humoral Responses Following Single Hydrogel Immunization of SARS‐CoV‐2 Subunit Vaccine
Authors: Ben S. Ou, Olivia M. Saouaf, Jerry Yan, Theodora U. J. Bruun, Julie Baillet, Xueting Zhou, Neil P. King, Eric A. Appel
Journal: Advanced Healthcare Materials (2023)

Most vaccines require several immunizations to induce robust immunity, and indeed, most SARS-CoV-2 vaccines require an initial two-shot regimen followed by several boosters to maintain efficacy. Such a complex series of immunizations unfortunately increases the cost and complexity of populations-scale vaccination and reduces overall compliance and vaccination rate. In a rapidly evolving pandemic affected by the spread of immune-escaping variants, there is an urgent need to develop vaccines capable of providing robust and durable immunity. In this work, a single immunization SARS-CoV-2 subunit vaccine is developed that can rapidly generate potent, broad, and durable humoral immunity. Injectable polymer-nanoparticle (PNP) hydrogels are leveraged as a depot technology for the sustained delivery of a nanoparticle antigen (RND-NP) displaying multiple copies of the SARS-CoV-2 receptor-binding domain (RBD) and potent adjuvants including CpG and 3M-052. Compared to a clinically relevant prime-boost regimen with soluble vaccines formulated with CpG/alum or 3M-052/alum adjuvants, PNP hydrogel vaccines more rapidly generated higher, broader, and more durable antibody responses. Additionally, these single-immunization hydrogel-based vaccines elicit potent and consistent neutralizing responses. Overall, it is shown that PNP hydrogels elicit improved anti-COVID immune responses with only a single administration, demonstrating their potential as critical technologies to enhance overall pandemic readiness.
Antigen‐Capturing Dendritic‐Cell–Targeting Nanoparticles for Enhanced Tumor Immunotherapy Based on Photothermal‐Therapy–Induced In Situ Vaccination
Authors: Yingmin Li, Yang Luo, Lamei Hou, Zhengjie Huang, Yi Wang, Shaobing Zhou
Journal: Advanced Healthcare Materials (2023)

In situ vaccines have revolutionized immunotherapy as they can stimulate tumor-specific immune responses, with the cancer being the antigen source. However, the heterogeneity of tumor antigens and insufficient dendritic cells (DCs) activation result in low cancer immunogenicity and hence poor vaccine response. Herein, a new in situ vaccine composed of acid-responsive liposome-coated polydopamine (PDA) nanoparticles modified with mannose and loaded with resiquimod (R848) is designed to promote the efficacy of immunotherapy. The in situ vaccine can actively target the tumor site based on the decomposition of the liposome, while the PDA nanoparticles promote photothermal therapy and capture the immunogenic cell-death-induced tumor-associated antigens based on the adsorption effect of dopamine-mimetic mussels. The PDA nanoparticles, which are modified with a mannose ligand, target the DCs and release R848 for activated antigen presentation. As a result, the in situ vaccine not only effectively activates the maturation of the DCs but also significantly enhances their effect on cytotoxic T lymphocyte cells. Furthermore, the vaccine effectively inhibits the distant recurrence and metastasis of tumors via long-term immune memory effects. Therefore, the in situ vaccine provides a potential strategy for improving the efficacy of cancer immunotherapy.
<scp>COVID</scp>‐19 associated oral and oropharyngeal microbiome: Systematic review and meta‐analysis
Authors: Sukirth M. Ganesan, Tabitha K. Peter, Miyuraj H. H. Withanage, Frank Boksa, Erliang Zeng, April Martinez, Shareef M. Dabdoub, Kunaal Dhingra, Yvonne Hernandez‐Kapila
Journal: Periodontology 2000 (2023)

Abstract Three years into the coronavirus disease 2019 (COVID‐19) pandemic, there are still growing concerns with the emergence of different variants, unknown long‐ and short‐term effects of the virus, and potential biological mechanisms underlying etiopathogenesis and increased risk for morbidity and mortality. The role of the microbiome in human physiology and the initiation and progression of several oral and systemic diseases have been actively studied in the past decade. With the proof of viral transmission, carriage, and a potential role in etiopathogenesis, saliva and the oral environment have been a focus of COVID‐19 research beyond diagnostic purposes. The oral environment hosts diverse microbial communities and contributes to human oral and systemic health. Several investigations have identified disruptions in the oral microbiome in COVID‐19 patients. However, all these studies are cross‐sectional in nature and present heterogeneity in study design, techniques, and analysis. Therefore, in this undertaking, we (a) systematically reviewed the current literature associating COVID‐19 with changes in the microbiome; (b) performed a re‐analysis of publicly available data as a means to standardize the analysis, and (c) reported alterations in the microbial characteristics in COVID‐19 patients compared to negative controls. Overall, we identified that COVID‐19 is associated with oral microbial dysbiosis with significant reduction in diversity. However, alterations in specific bacterial members differed across the study. Re‐analysis from our pipeline shed light on Neisseria as the potential key microbial member associated with COVID‐19.
Pulse Oximeters and Federal Antidiscrimination Law
Authors: Alexander A. Hannenberg, Alan F. Merry
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Conflict of Interest Disclosures
Journal: JAMA Network Open (2023)

Sara K. Redd, PhD, MSPH; Elizabeth A. Mosley, PhD, MPH; Suba Narasimhan, PhD, MPH; Anna Newton-Levinson, PhD, MPH; Roula AbiSamra, MPH; Carrie Cwiak, MD, MPH; Kelli Stidham Hall, PhD, MS; Sophie A. Hartwig, MPH; Johanna Pringle, MPH; Whitney S. Rice, DrPH, MPH
The future of artificial intelligence in intensive care: moving from predictive to actionable AI
Authors: Jim M. Smit, Jesse H. Krijthe, Jasper van Bommel, M.E. van Genderen, J.A. Labrecque, M. Komorowski, D.A.M.P.J Gommers, M. J. T. Reinders
Journal: Intensive Care Medicine (2023)
Pulse Oximeters and Federal Antidiscrimination Law—Reply
Authors: Annabel Kupke, Christopher T. Robertson, Carmel Shachar
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal